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β-sheetAmyloid refers to insoluble protein aggregates that are responsible for amyloid diseases but are also implicated in
important physiological functions (functional amyloids). The widespread presence of protein aggregates but also,
inmost of the cases, their deleterious effects explainworldwide effortsmade to understand their formation, struc-
ture and biological functions. We emphasized the role of FTIR and especially ATR-FTIR techniques in amyloid pro-
tein and/or peptide studies. Themultiple advantages provided by ATR-FTIR allow an almost continuous structural
view of protein/peptide conversion during the aggregation process. Moreover, it is now well-established that in-
frared can differentiate oligomers from ﬁbrils simply on their spectral features. ATR-FTIR is certainly the fastest
and easiestmethod to obtain this information. ATR-FTIR occupies a key position in the analysis and comprehension
of the complex aggregationmechanism(s) at the oligomer and/or ﬁbril level. Thesemechanism(s) seem to present
strong similarities between different amyloid proteins andmight therefore be extremely important to understand
for both disease-associated and functional amyloid proteins. This article is part of a Special Issue entitled: FTIR in
membrane proteins and peptide studies.
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l rights reserved.1. Introduction
Amyloid refers to insoluble protein aggregates that are responsible
for amyloid diseases (e.g. Alzheimer's, Parkinson's, Huntington's,
prion's diseases, type II diabetes, and also some cancers) affecting
large populations worldwide [1,2]. But they are also implicated in the
binding and storage of peptide hormones in the brain, formation of
bacterial bioﬁlms, melanin formation and initiation of antiviral innate
immune response (this latter category is nowadays referred to as
“functional amyloids” and the number of proteins involved in these is
2329R. Sarroukh et al. / Biochimica et Biophysica Acta 1828 (2013) 2328–2338expected to increase rapidly in the near future) [3–7]. The widespread
presence of protein aggregates but also, in most the cases, their delete-
rious effects explainworldwide effortsmade to understand their forma-
tion, structure and biological functions [8].
Amyloid ﬁbrils present an unbranched ﬁlamentous morphology [9]
and are characterized by β-strand repeats running perpendicular to the
ﬁber axis. This structure named cross-β is a unique motif among protein
folds [2,10].Whether any protein is able to form amyloids is still amatter
of debate and reassesses our current knowledge underlying the princi-
ples of protein folding, misfolding and aggregation. Two apparently
contradictory theories are currently proposed. The ﬁrst one postulates
that ﬁbril formation is a general property occurring for any polypeptide
chain in some circumstances (sometimes far from any physiologically
relevant conditions) [11], while the second restricts their formation to
speciﬁc proteins collectively classiﬁed as the ‘amylome’ [12].
Extensive efforts have been carried out during the past few years to
understand the pathways leading to this structural conversion [13]. Fi-
bril formation is presently described by a two-step process. The nucleat-
ed conformational changes conversion of the native polypeptide chain
promotes oligomer species (Fig. 1). This ﬁrst step is often subdivided
into a lag phase and a nucleation phase. The elongation process leads
to mature ﬁbrils by a self-template growth mechanism [14–16]. Fibrils
can also undergo fragmentation which enhances the kinetics of the
aggregation process by increasing their number and suppressing the
limiting step of misfolded conformer's production [17–19]. Those two
misfolding processes are not exclusive and may occur concomitantly.
The common structural motif shared by ﬁbrils for all amyloidogenic
proteins have suggested a common mechanism of aggregation and tox-
icity [20–22].Why and howprotein aggregates is largely not understood.
Moreover, during the aggregation several species are formed and do not
contribute in the sameway to cell toxicity. It is not clearwhether speciﬁc
species (ﬁbrils [23], oligomers [24,25]) or membrane-associated confor-
mational changes [26,27] lead to cell death. This raises the question of a
relationship between structure and cytotoxicity [28–34].Fig. 1. Schematic representation of the aggregation process of amyloid proteins. This scheme d
the end of the nucleation phase and before the elongation one. During the nucleation phase, n
bigger particles (collectively called oligomers). During the elongation phase, addition of mis
protoﬁbrils aimed at ﬁbril formation.Fibrils have been characterized usingmultiple biophysical techniques
such as Electron Microscopy (EM) [9,35,36], Atomic Force Microscopy
(AFM) [37–40], Electron Paramagnetic Resonance (EPR) [41–44] and at
higher resolution using solid state Nuclear Magnetic Resonance
(ssNMR) [45–50] and X-ray diffraction [9] (for reviews see [10] and
[2]). On the other hand, little information on the structure and properties
of oligomers is available and no real agreement has been currently
reached to describe their function in the whole aggregation process
[10,45,51–53] (Fig. 1).
As previously mentioned, biophysical tools have been nicely
exploited to provide important information regarding the 3D structure
of ﬁbrils [35,54–56]. The main limitation of these high resolution
techniques is the important amount of protein material required, the
recording time and the necessity to deal with insoluble (or at least hy-
drophobic or amphipathic) aggregates which above all are in constant
equilibrium between different aggregated states. Fourier-transform in-
frared spectroscopy (FTIR) offers a unique opportunity to overcome
those limitations and allows the characterization of the aggregates
formed during the aggregation. Recording time is short, preventing
time dependent structural changes. A few μg of protein is sufﬁcient to
evaluate the secondary structure of aggregates. Moreover, contrary to
circular dichroism (CD), in FTIRβ-sheet contribution has the highest ab-
sorption coefﬁcient; therefore FTIR is particularly well-adapted to ana-
lyze β-sheet-rich proteins. Keeping all the advantages of “classical”
FTIR, attenuated total reﬂection (ATR) (sometimes also referred to as at-
tenuated total reﬂectance) FTIR provides additional extremely useful
features when studying amyloid proteins. ATR-FTIR overcomes the
problem of insolubility because the sample is analyzed as a thin ﬁlm
on the surface of an internal reﬂection element (IRE). Moreover, pro-
teins (and more generally molecules) in this thin ﬁlm can be oriented;
therefore, linear dichroism experiments can provide useful information
about the relative orientation of the corresponding dipoles which could
then be related to the orientation of secondary structures. Recent ATR
devices require less than 100 ng of proteins to record good qualityisplayed different entities or ‘particles’ observed along the process including oligomers at
ative monomers are transformed into misfolded ones and then started to aggregate into
folded monomers and/or oligomers at the extremities of protoﬁbrils and association of
2330 R. Sarroukh et al. / Biochimica et Biophysica Acta 1828 (2013) 2328–2338spectra. Many excellent reviews have been published over the years de-
scribing all the properties and advantages of ATR-FTIR [57–64].
2. Structural features of amyloid ﬁbrils highlighted by (ATR)-FTIR
spectroscopy: a brief survey
Fibrils are currently well-characterized structurally. The diffraction
pattern of cross-β ﬁbrils was ﬁrst observed by Astbury in 1935 [65],
and next modeled by Corey and Pauling [66]. Fibril structures are
made of proteins/peptides or protein segments stacked along the ﬁber
axis. The packing results in protein sheets running parallel to each
other.
2.1. FTIR and amyloid ﬁbrils: a tentative clariﬁcation of a historical
putative mistake
While FTIR spectroscopy was used since early 1970 to investigate
amyloid ﬁbrils [67,68], the apparent discrepancy between the IR spec-
tral analysis and later NMR ﬁndings about ﬁbrils [47,55,69] have for a
long time put FTIR in the shade when coming to ﬁbril analysis. Indeed,
the ﬁrst results obtained demonstrated that ﬁbrils displayed a typical
anti-parallel β-sheet structure characterized by two bands in the
amide I: a low frequency, high intensity band around 1620–
1630 cm−1 and a high frequency, low intensity band located around
1685–1695 cm−1. Extensive theoretical and experimental works have
demonstrated that the simultaneous presence of these two bands is
assigned to anti-parallel β-sheet while the presence of only the low fre-
quency band around 1630–1640 cm−1 is attributed to parallel β-sheet
[70–75]. Unfortunately, latter NMR studies [47,55,69] and nowadays
high resolution structure [76–79] all pointed to parallel β-sheet struc-
ture in the vast majority of amyloid ﬁbrils.
Therefore, FTIR was supposedly wrong and it was stated that ﬁ-
brils had speciﬁc and non-typical β-sheet spectral features. Since
then FTIR was only used to prove the presence and especially the in-
crease of β-sheet content upon ﬁbrillization without further assign-
ment of the relative orientation of the strands in the sheet. It is true
that in some cases, especially with ATR-FTIR, special care should be
taken when recording and analyzing protein spectra, as elegantly
demonstrated by Keith Oberg while in Tony Fink's lab [80]. Later on,
the late and highly regretted Tony Fink also demonstrated that
speciﬁc supersecondary structures like beta-helices could lead to un-
expected spectral features [81].
Nevertheless, at the turn of the century, a few works on some
well-deﬁned amyloid ﬁbrils indicated that the remaining high frequen-
cy band (1685–1695 cm−1) could be due to residual other structures in
the samples. Bouchard et al. inDobson's and Robinson's lab [82] showed
that insulin at pH 2.3 aggregates upon heating at 70 °C. While the FTIR
spectrum once more showed the two typical bands for anti-parallel
β-sheet for short incubation times, upon longer incubation (18 h) the
high frequency component at 1690 cm−1 completely vanished consis-
tent with a parallel β-sheet organization. Zurdo et al. [83] incubated at
low pH a Src homology 3 domain (SH3) domain of the β subunit of bo-
vine phosphatidylinositol-3′-kinase. To demonstrate that no other
structure than ﬁbrils is present in the sample, they add pepsin to digest
any non-ﬁbrillar structure (amyloid ﬁbrils are highly resistant to prote-
olysis). During the pepsin treatment, FTIR spectra showed the disap-
pearance of the high frequency band of the β-sheet contribution. A
nine residue peptide from Sup35 forming amyloid-like crystals has
been studied by Balbirnie et al. in Eisenberg's lab [84]. Extremely pure
and well-characterized, this crystal was submitted to FTIR and showed
only the low frequency band (1633 cm−1) typical of parallel β-sheet.
This could explain the discrepancy between early works and more
recent applications of FTIR in ﬁbril studies. Moreover, if mature ﬁbrils
made by full length amyloid proteins are essentially in a parallel
β-sheet conformation, we think it is now well-accepted that shorter
peptides (usually encompassing only one strand) have a higherpropensity to adopt an anti-parallel conformation. Also, for decades, no-
body in the ﬁeld had imagined that other structures like oligomers (see
below) could even exist and can be in a dynamic equilibrium with
ﬁbrils.
Despite this historical “glitch”, FTIR played an important role in
the study of amyloid ﬁbrils, as we will brieﬂy survey here with a spe-
ciﬁc emphasis on ATR-FTIR when possible. We refer the reader to the
more exhaustive and excellent review on this topic by P.H. Axelsen in
this same issue.
2.2. Studying the β-sheet structure formation
In the early 1990s, the pioneering work on amyloid ﬁbrils carried
out by Gasset and Baldwin in Stanley Prusiner's group [85,86] reported
for the ﬁrst time the β-structure signature of amyloids using ATR-FTIR
with bands at 1685–1695 and 1623 cm−1 in the amide I band. Conver-
sion of the cellular prion protein (PrPC) to its infectious form PrPSc is
associated with a decrease in the α-helical and turn structures and an
increase in the β-sheet structure [87]. More importantly, a quantiﬁca-
tion of the secondary structure demonstrates that increasing β-sheet
content in prion rods is accompanied by an assembly into ﬁbrils and
an increase in infectivity [85,86]. This was extremely important infor-
mation to reinforce the Prusiner's prion theory.
Later, comparing globular proteins (with at least 30% of β-sheet
structure) to amyloid ﬁbrils revealed amajor difference in the band po-
sition assigned to β-structure [88]. For example, transthyretin (TTR) in
its globular state displays an absorption maximum in the Amide I
band located at 1630 cm−1 and at 1615 cm−1 while in ﬁbrils.
In conclusion, amyloidﬁbrils have a spectral signature clustering be-
tween 1611 and 1630 cm−1, while for native β-sheet proteins it ex-
tends from 1630 to 1643 cm−1. These differences are correlated to
inherent β-sheet properties like the assemblage in longer sheet, longer
β-strand formation as well as more planar sheet formation [89,90].
More recently, we used ATR-FTIR to study well-characterized and
well-deﬁned amyloid ﬁbrils made with Alzheimer's amyloid-β pep-
tides (Aβ), Aβ 42 [29], Aβ 40 [91] (Fig. 2A, a–d), α-synuclein [33],
and lysozyme [92]. In all cases, we could observe only the low fre-
quency peak (around 1626–1630 cm−1) characteristic of parallel
β-sheet demonstrating that ATR-FTIR is also a convenient and versa-
tile tool to study amyloid ﬁbril structures.
2.3. Conformational changes promoting ﬁbril formation
Highlighting and understanding the initial conformational changes
favoring the structural formation of ﬁbrils is a challenging process in
protein folding and misfolding. Due to the repeated structure motif ob-
served in ﬁbrils, studies started to investigate molecular events that
might inﬂuence β-hairpin formation and/or stabilization like secondary
structure conversion, β-turn formation and possible side-chain interac-
tions stabilizing β-sheets.
Independent detection of secondary structures on IR spectrum al-
lows demonstrating that β structure (1637–1613 cm−1) is promoted
by the destabilization of the α-helices (1662–1645 cm−1) for various
systems like Aβ [93], the insulin protein [82,94] and β lactoglobulin
[95]. Janek et al. demonstrated for Aβ 42 that a substitution of
L-amino acids by their D-enantiomers directed formation of ﬁbrils
(increase in 1634 cm−1 peak) by destabilizing α-helices (1654 cm−1)
along the Aβ 42 peptide [96]. They highlighted that substitution located
in a region encompassing residues 11–24 in monomers promoted
β-sheet structures to a larger extent compared to substitution in other
regions [96].
Those data raised the link between α-to-β conformational changes
and amyloidogenicity of proteins as earlier proposed by Prusiner on
fragments of PrP [87]. In line with this observation, Murakami et al.
[97] provide the ﬁrst predictions of secondary structure content by an-











Fig. 2. Assessments of Aβ 42 ﬁbrils (A) and oligomers (B). (a) ATR-FTIR spectra in the amide I region of Aβ 42. In B, a red line is shown at 1695 cm−1 to facilitate the identiﬁcation of the
major difference between spectra; (inserts) 1 μm × 1 μmcontactmodeAFM images of the corresponding Aβ 42. (b)Westernblot analysis of the sampleswithmonoclonal antibody 6E10.
(c) Dot–blot analysis of Aβ 42 ﬁbrils (panel A) and oligomers (panel B) with the conformation-dependent A11 antibody. (d) Corresponding ThT ﬂuorescence emission spectra.
2331R. Sarroukh et al. / Biochimica et Biophysica Acta 1828 (2013) 2328–2338peptides (naturalmutations). Freshwild-type peptide displays 48% of β
structure while mature ﬁbrils contain 58%. All ﬁbril-forming mutants
showed an increase in β-sheet content (contribution between 1620
and 1640 cm−1) in monomers correlated to greater amyloidogenicity
[97].
Besides the α-to-β conformational changes, it has been argued that
a β-turn formation is the critical limiting step leading to β-hairpin ob-
served in ﬁbrils [97–99]. Replacing amino acid pairs in the turn region
of Aβ (residues 24–27) with DProGly (an effective turn-nucleating
motif) modulated ﬁbril formation. β-sheet content increases with a
maximum intensity change around 1628 ± 2 cm−1 consistent with a
cross-βmorphology [98].Finally, inﬂuence of aromatic amino acids on β-sheet formation is a
matter of debate and raised questions on whether their hydrophobicity
or formation of stabilizing π–π interactions can promote peptide
self-assembly [100]. A truncated model of Islet Amyloid Polypeptide
protein (IAPP) (aa 20–29) containing only one aromatic residue at posi-
tion 23 (Phe 23)was used to clarify this role because this side-chainwas
demonstrated not to participate in cross-β structure [69]. Different IAPP
variants at position 23 (Tyr, Leu, Phe, pentaﬂuorophenylalanine
(F5-Phe), cyclohexylalanine (Cha), α-naphthylalanine (1-Nap), and
β-naphthylalanine (2-Nap)) were therefore engineered to clarify the
contributions of steric, hydrophobic, and π-π effects on peptide
self-assembly. Tyr, Leu, and Phe are aromatic amino acidswith different
2332 R. Sarroukh et al. / Biochimica et Biophysica Acta 1828 (2013) 2328–2338hydrophobicity (Tyr b Leub, Phe) but unlike Leu, Phe and Tyr have pla-
nar aromatic side chains. The other mutation models result in an in-
crease in hydrophobicity and a change in steric proﬁle (Cha has no
planar side chains while 1-Nap and 2-Nap are planar). Fibril growth
was controlled by FTIR. The position of the β-sheet at 1626 cm−1 on
spectra demonstrates that mutants display β structure related to
amyloid. Compelling β-sheet studies provided by FTIR, kinetic response
to an amyloid speciﬁc ﬂuorescent dye (e.g. Thioﬂavin T, ThT) and TEM
images demonstrate that high amyloidogenicity of aromatic amino
acids is a function of hydrophobicity and not the ability to form stabiliz-
ing or directing π–π bonds. Besides, site-speciﬁc analysis of secondary
structures at this position 23 was probed by isotope-edited Fourier
transform infrared. Isotope labeling by 13C results in a shift in absorp-
tion to smaller wavenumbers (by ~35–40 cm−1) and therefore a sepa-
ration of 13C_Ovibration from the unlabelled 12C_O is visible allowing
speciﬁc assignment of secondary structure to the labeled amino acid.
Isotope-edited FTIR is an extremely powerful method which has been
applied to amyloid local structure determination and also to the respec-
tive alignment of residues in ﬁbrils [101,102]; for more information see
the excellent review on this speciﬁc topic by I. Arkin in this issue. All
mutants display the same amide I isotopic shifted band at 1605 cm−1
demonstrating that they form the same β-sheet packing [100].
2.4. Polarized FTIR methods, an alternative method to X-ray diffraction
powder patterns to study ﬁbrils
Linearly polarized ATR-FTIR method is a spectroscopic technique
used to determine the orientation of functional groups within the
proteins in highly ordered systems, like membranes. [58,59,61]. This
method is based on the property that the intensity of IR light absorption
depends on the relative orientation of the transition dipolemoment and
the exciting electricﬁeld of the incident light. Absorption becomesmax-
imal when the transition dipole moment is parallel to the electric ﬁeld
of the incident light. Therefore, recording two IR spectra of an oriented
sample with light polarized perpendicular to each other allows the de-
termination of the relative orientation. A difference spectrum (dichroic
spectrum) is calculated and its analysis allows both qualitative and
quantitative estimation of the orientation of dipoles related to speciﬁc
vibrations (for a complete description of this method sees the following
references [103,104]).
Given the known conformation of ﬁbrils, a large body of data dem-
onstrates that the polarized FTIR method could be quickly use to verify
if aggregate preparations are in cross-β spine conformation. For that
purpose, ﬁbrils are aligned by air-blowing procedure on a surface: IRE
in ATRmode or CaF2 windows for transmission mode. Fibrils are forced
to align by moving along the surface by the air-jet. Orientation study is
next performed by analyzing three important bands in the dichroic
spectrum. Amide A (3000–2840 cm−1, N\H stretching mode of vibra-
tion of the peptide bond), Amide I (1600–1700 cm−1, C_O stretching
of the peptide bond) and Amide II (1600–1500 cm−1, mainly N\H
bendingmode of vibration). Amide A and I are expected to have a resul-
tant dipolemoment perpendicular to the backbone but alignedwith the
ﬁber axis. Amide II's dipole moment on the contrary, is parallel to the
backbone [105–110]. Recently, such a linear dichroic analysis was
performed showing that evenwith non-orientedﬁbrils cross-β patterns
could be determined [110]. This analysis is only valuable for ﬁbrils and
not for oligomers which are globular shaped and displayed high anisot-
ropy. Even if X-ray diffraction remains the ‘golden’ technique to charac-
terize the cross-β conformation, the polarized ATR-FTIR method on
aligned samples is also a quick and suitable complementary method.
3. ATR-FTIR and the new amyloid cascade: a
structural breakthrough
In the last ~15 years, the amyloid cascade hypothesis has been
revisited to include new “player(s)” in the ﬁeld: the oligomers.Unfortunately, the term oligomer refers to any aggregated but still
soluble particle of the amyloid protein or peptide involved, no matter
its size or other properties. Oligomers in the literature are also called
globulomers, amyloid-beta derived diffusible ligands (ADDLs),…No
single deﬁnition or precise nomenclature exists so far [111].
Due to the emerging role of these species in amyloidosis' aetiology,
the new amyloid cascade hypothesis was enounced. The ﬁbrils are not
the most important structure anymore at least in terms of toxicity. In-
deed, clear observations especially in Alzheimer's disease (AD) demon-
strated that the disease symptoms were not correlated with plaque
burden (number or size) but more likely with oligomer formation. In
somediseases (e.g. AD), oligomersmight even be present decades before
any visible cognitive defects [112]. Other studies on cellular systems
clearly demonstrated the high toxicity of the oligomers compared to ﬁ-
brils [113]. An emerging idea is that amyloid ﬁbrils might be a sort of
ﬁnal, less toxic, storing element for these proteins or peptides in their
detrimental conformation [114]. While oligomers have been identiﬁed
in almost all disease-associated proteins/peptides, it seems they also
exist for functional amyloid [3].
As soon as researchers demonstrated the highly toxic character of
oligomers, intensive research on their topology, structure and of
course on their toxic mechanism(s) were carried out.
From a topological and size point of view, nothing has been formally
demonstrated yet. For Aβ, some groups assume that toxicity is already
associated with dimers [115] while others think at least tetramers (or
a multiple of these) are required [116]. Just like ﬁbrils, oligomers are
SDS-resistant and can therefore be observed by SDS-PAGE (being par-
ticularly cautious and using other techniques to conﬁrm the observed
results as carefully demonstrated by Bitan and Teplow in their seminal
paper: “What you see is not alwayswhat you get” [111]). First cognitive
impairments were even associated with the apparition of a dodecamer
of Aβ (Aβ*56) in the brain of model mice [117]. Nevertheless, so far no
conclusive answer has been given to which oligomer in particular is the
most toxic.Most probably, the intrinsic polymorphismdue to highly dy-
namic reorganization in oligomer populations is required to obtain
“full” toxicity [27].
Moreover, the exact mechanism(s) of toxicity is still far from
being completely understood (for review see [118]). Interaction
with membranes is considered as one of the most probable mecha-
nisms or at least as a ﬁrst step [119–124]. But other (non exclusive)
possibilities have been suggested such as impairment in calcium ho-
meostasis, oxidative stress, mitochondrial impairment, activation of
the innate immune system…
From a structural point of view, it was rapidly demonstrated that
oligomers were rich in β-sheet. It was therefore assumed they
adopted the same cross-β structure as ﬁbrils and were just
“nascent” (proto)ﬁbrils [125]. Due to their smaller size, they could
interact more rapidly and easily with cells and exert more toxic
effects.
Like ﬁbrils, oligomers formed from different amyloidogenic proteins
or peptides showed some singular similarities in their topology. De-
scribed as globular or spherical, most of the oligomers from different
proteins/peptides studied can form round- or ring-shaped structures
as identiﬁed by EM or AFM [37]. All these elements pointed to the
same conclusion already obtained for ﬁbrils: oligomers share the same
structure and mechanism(s) no matter the protein/peptide they origi-
nated from.
An important structural breakthrough came from Charles Glabe's
group. They devised a conformational antibody, A11, directed against
Aβ oligomers (at least against species bigger or equal to heptamers).
This antibody was not reactive against Aβ ﬁbrils. More importantly,
when applied to oligomers formed by other amyloidogenic proteins
(see below), A11 was reactive showing that indeed oligomers shared
a common structure but different from ﬁbrils [21]. Soon after, other
conformational anti-oligomers antibodies were obtained aiming at
the same results [126].
2333R. Sarroukh et al. / Biochimica et Biophysica Acta 1828 (2013) 2328–2338Due to their aggregated state, their relatively high hydrophobicity
(e.g. ANS binding), their heterogeneity in size and their high content
in β-sheet, ATR-FTIR is well-indicated to evaluate oligomer's secondary
structure(s).
Very ﬁrst reports displaying FTIR spectra of oligomers indicated
that they were compatible with a high content in β-sheet.
3.1. Anti-parallel β-sheet is the spectral feature of oligomers
Starting with Aβ 42 and using well-deﬁned protocols, we formed
oligomers devoid of any ﬁbrils as assessed by Western blot, AFM, ThT
ﬂuorescence and A11 dot blot analyses. An ATR-FTIR analysis of these
well-characterized oligomers demonstrated an anti-parallel orientation
of theβ-strands in the peptide due to the presence of both low and high
frequency bands of the β-sheet. As previously mentioned, Aβ 42
well-characterized ﬁbrils displayed only the low frequency band char-
acteristic of parallel β-strands. The respective intensity of the two
bands is in perfect agreement with a 100% anti-parallel alignment
when compared to spectra of all anti-parallelβ-sheet proteins [29]. Fur-
thermore, the Aβ 42 oligomer spectrum displayed striking similarities
with membrane β-barrel porin spectrum. Based on this fact and that
A11 conformational antibody developed by Kayed et al. [21] recognizes
a wide variety of amyloidogenic oligomers (Aβ, hIAPP, α-synuclein,
lysosyme, insulin) as well as pore-forming proteins (α-hemolysin, …)
[127], we suggested that Aβ 42 oligomers might adopt a porin-like
β-barrel conformation.
Applying similar procedures and ATR-FTIR to other amyloid protein
oligomers, we demonstrated that Aβ 40 (Fig. 2), Aβ 40 arctic mutant,
α-synuclein, all displayed characteristic anti-parallel orientation of
their β-strands. The presence of this speciﬁc structure was observed in
other amyloid proteins/peptides (see Table 1) like β2-microglobulin
[128], prion-related peptide PrP82-146 [129], transthyretin (TTR) [130],
lysozyme [131,132], HETs prion protein (prion of the ﬁlamentous fun-
gus P. anserine) [30] and SRC Homology 3 Domain (SH3 domain) [83].
Most of these articles barely mentioned that their oligomeric prepara-
tions have FTIR spectral features compatible with an anti-parallel
β-sheet conformation, most if not all of these did not use any of this in-
formation in their conclusions. Altogether this demonstrated that
anti-parallel β-sheet is the major conformational contribution in oligo-
mers. This might, especially when considering the potential formationTable 1
Infrared and species assignments for several amyloid proteins/peptides.
Protein name Species/entities Assignment based on
Aβ peptide Aβ 42 oligomers ThT ﬂuorescence, A11 response
Aβ 42 ﬁbrils
Aβ 42CC oligomers/protoﬁbrils ThT ﬂuorescence, A11 response
Aβ 40 oligomers ThT ﬂuorescence, A11 response
Aβ 40 ﬁbrils
Aβ 40 oligomers ThT ﬂuorescence, A11 response
Aβ 40 ﬁbrils
α-synuclein α-Syn oligomers ThT ﬂuorescence, A11 response
α-Syn ﬁbrils
α-Syn oligomers ThT ﬂuorescence, SEC, SAXS, EM
β2-microglobulin β2m short curved structures Light Scattering and EM
β2m ﬁbrils
PrP82-146 PrP82–146 oligomers EM, AFM and Laser scanning co
microscopyPrP82–146 ﬁbrils
Transthyretin TTR soluble aggregates Light scattering, ANS ﬂuorescen
TTR ﬁbrils
Lysosyme Lysosyme oligomers ThT and ANS ﬂuorescence, EM,
Fibrillar aggregates at pH 7.5 SDS-PAGE, EM, X-ray diffractio
Fibrillar aggregates at pH 2.0
HETs prion protein HET-s(218–289) ﬁbers Turbidity and Congo Red bindi
HET-s(218–289) ﬁbers
SH3 domain Amorphous aggregates EM, SDS-PAGE
SH3 ﬁbrilsof porin-like β-barrel for these proteins, be important on the one hand
for the differentiation between oligomers and ﬁbrils and on the other
hand for the comprehension of the huge difference observed in cytotox-
icity for both species (oligomers vs. ﬁbrils).
Early 2012, this conclusion has been further strengthened by
X-ray derived atomic structure of a segment of αB crystallin sharing
sequence homology with Aβ peptide and forming A11-positive oligo-
mers. The high-resolution structure of these αβ crystallin oligomers
demonstrated the formation of an anti-parallel β-barrel made of six
strands [53,125]. The anti-parallel alignment of the β-strands in olig-
omers have also been evidenced by time-resolved hydrogen ex-
change mass spectrometry on Aβ oligomers [133], and an exemplar
analysis by NMR of a very low percentage of oligomers of Fyn SH3
in the presence of the correctly folded protein [134].
Therefore, ATR-FTIR is a handy, rapid and versatile method to
evaluate the secondary structure of various amyloid aggregates and
to shed light on oligomer presence in a sample (Fig. 2).
3.2. Is the anti-parallel β-sheet structure a signature of amyloid cytotoxicity?
Oligomers can exert several harmful effects on the viability and
functions of cells [28,135–141]. Today, even if no consensus on oligomer
targets is reached, the hypothesis of a uniquemechanismbywhich olig-
omers might be toxic has been proposed. As postulated by Bucciantini
et al. [135], this mechanism may be linked to common conformational
features rather than speciﬁc properties of proteins or peptides.
Considering the increasing number of polypeptide chains adopting
anti-parallel structure in their oligomeric conformation, we may inter-
rogate if anti-parallel β-sheet is the signature for cytotoxicity
[21,28,135].
Our observation as well as literature data [142] and the previously
mentioned fact that A11 conformational antibody raised against oligo-
mers also recognized pore-forming proteins, suggest that oligomers
may adopt a pore-like morphology, an especially favorable conformation
to interact in a detrimental way with lipid membranes. This hypothesis
corroborates many experimental evidences nicely reviewed in [137].
A correlation between cytotoxicity and the anti-parallel β-sheet
structure was recently demonstrated by two different studies
[30,31]. First, Sandberg and coworkers in Härd's laboratory [31] de-
veloped an extremely elegant approach by mutating A21 and A30FTIR method Main β-sheet peak(s)
(cm−1)
Ref.
Low freq. High freq.
, SDS-PAGE and AFM ATR-FTIR 1626 1695 [29]
1630 –
, SDS-PAGE, SEC and EM FTIR 1630 1691 [31]
, SDS-PAGE and AFM ATR-FTIR 1632 1695 [91]
1627 –
, SDS-PAGE and AFM ATR-FTIR 1633 1694 [150]
1629 –
, SDS-PAGE and EM ATR-FTIR 1630 1694 [33]
1628 –
and AFM ATR-FTIR 1630 1687 [152,153]
FTIR 1616 1685 [128]
1620 –
nfocal ﬂuorescence FTIR 1623 1690 [129]
1626 –
ce FTIR 1616 1686 [130]
1625 –
SDS-PAGE, FTIR 1630 1688 [131]
n ATR-FTIR 1628 1692 [132]
1622 1693
ng ATR-FTIR 1620 1695 [30]
1630 –
FTIR 1612 1684 [83]
1618 –
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42cc when in oxidative conditions form an intramolecular disulﬁde
bond which stabilized the oligomers and entirely blocked the forma-
tion of ﬁbrils. ATR-FTIR demonstrated that these stable oligomers
adopted anti-parallel β-sheet structure. More importantly, these olig-
omers were 50 times more efﬁcient apoptotic agents than ﬁbrils.
When suppressing the disulﬁde bond using reducing conditions, the
peptides started to quickly form classical Aβ ﬁbrils and became less
toxic.
Later, Berthelot et al. demonstrated that mutagenesis of nontoxic
amyloidogenic prion forming domain of HET-s yields to the modula-
tion of β-structure conformation. It correlated to cytotoxicity on
yeast cells. Mutations promoting anti-parallel β-sheet structure are
toxic to yeast in regard to those promoting parallel and random coil.
Moreover, they demonstrate that mutant displaying anti-parallel
β-sheet structures interact strongly and disturb the lipid monolayer
thickness while non toxic mutants were unable to have such toxic
functions [30].
Those data emphasize the emerging hypothesis of the anti-parallel
β-sheet conformation as a signature of amyloid oligomers and cyto-
toxicity. Nevertheless, no consensus is reached so far to describe the
molecular mechanism(s) of cytotoxicity.
4. FTIR as a tool to structurally follow the aggregation process
FTIR is an exquisite technique to follow structural changes along
the aggregation process. Indeed, as previously mentioned, samples
are quickly prepared, spectra are extremely rapid to record, and
only minor protein quantities are required. ATR-FTIR has the added
advantage to be able to handle hydrophobic and/or insoluble sam-
ples. FTIR is therefore one of the rare methods able to give an almost
continuous structural view of such processes.
Starting frommonomers or oligomers, an intriguing question is how
β-strands (re)organize themselves into a different type of β-sheet
when ﬁbrils are formed. To investigate this, Decatur's group used
isotope-edited (13C-labeled carbonyl) infrared spectroscopic technique
on PrP and Aβ short peptides. As mentioned above, introduction ofa
b
Fig. 3. (ATR)-FTIR as a tool to structurally follow the aggregation process (use of β-index
β-structure (I1695/I1630) is proportional to the percentage of anti-parallel vs. parallel orga
“β-index” for short. We followed the time evolution of this index during the aggregation pro
the peptide displayed the 1630 and 1695 cm−1 bands characteristic of anti-parallel β-sheet
resulting in only one major β-sheet spectral contribution around 1630 cm−1, assigned to pheavier 13C at one residue results in a shift in its absorption to smaller
wavenumbers resulting in a separation from unlabeled 12C backbone
absorption band. Spectra analysis reveals the local secondary structure
of the labeled amino acid according to its band position. The observed
band shift is also dependent on residue alignment. When labeled
residues are aligned in all the β-strands forming the sheet (i.e. they
are in register) an additional shift to lower frequency of maximum
~10 cm−1 is observed due to a vibrational coupling effect [143].
Different mutants of PrP109–122 labeled with 13C at residues implicated
in β-structure (one residue at a time) have been used to probe the
organization of strands (i.e. the relative alignment of labeled residues)
by following the shift in the maximum of absorption (from 1601 to
1592 cm−1) and stability upon aggregation by quantifying the
β-sheet content. They demonstrated that PrP109–122 reorganized their
β-strands by a dynamic alignment promoted by repeated detachment
and annealing of β-strands to ﬁnally form stable ﬁbrils [144]. The
same behavior was observed for truncated Aβ aa 16–22 [145]. Together
with morphology studies by AFM of ﬁbrils (thickness, ﬂexibility
and twist), they conclude that a correlation exists between strands
(re)organization and aggregation.
Kinetic analysis of aggregation has been next investigated by
time-resolved IR spectroscopy [146]. Perálvarez-Marín et al. used pH
jump triggered by photolytic release of a caged-proton to promote ag-
gregation of truncated Aβ (aa 1–28). Spectra were recorded on a
sub-millisecond time-scale upon aggregation. Data showed that the
ﬁrst step corresponds to a rapid (3.6 s) increase in β-structure intensity
at 1623.5 cm−1. This is related to small β-sheet aggregates formation.
After that a second slower (48 s) step takes place and leads to formation
of large aggregates displaying a major peak at 1619.5 cm−1. Those data
surprisingly demonstrate that partially aggregated species absorbing at
1623.5 cm−1 corresponding to oligomers are the initial step inﬁbril for-
mation [146].
More recently, higher resolution techniques (X-ray and ssNMR)
demonstrated that soluble, globular, high molecular weight oligo-
mers (i.e. close to ﬁbrils, they are indeed ThT positive) can adopt ei-
ther a cross-β conformation containing anti-parallel β-sheet [125]




). It was suggested that the intensity ratio between the two spectral contributions of
nization of the β-strands. We called this ratio the “β-sheet organizational index” or
cess of Aβ 42. Insert: Amide I analysis demonstrated that at early stages of aggregation
organization (curve a). When ﬁbril formation took place, the 1695 cm−1 disappeared
arallel β-sheet structure (curve c).
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and ﬁbrils might adopt a combination of the different structural fea-
tures of both entities. Therefore, it is tempting to suggest that this
conversion is a complex but nevertheless quite progressive and con-
tinuous process. New ATR-FTIR results obtained on Aβ are in perfect
agreement with this idea (unpublished data). This needs conﬁrma-
tion on other amyloidogenic proteins before drawing a deﬁnite con-
clusion on the involvement of these interesting intermediate species
in the aggregation process.
The oligomers-to-ﬁbrils transition was also depicted using ATR-FTIR
in our recent Aβ studies [91] (Fig. 3). We demonstrated that the
misfolding process for wild type Aβ 42 and Aβ 40 peptide is supported
by β-sheet reorganization. Amide I ﬁngerprint analysis demonstrates
that at the early stages of aggregation both peptides display the 1630
and 1695 cm−1 bands reported for anti-parallel β-sheet organization.
When ﬁbril formation takes place, the 1695 cm−1 disappears resulting
in only one β-sheet contribution around 1630 cm−1, assigned to
parallel β-sheet structure. This conversionwas suggested to be thermo-
dynamically favorable by molecular dynamics (MD) simulations
[147,148]. Nevertheless, evidences for a dynamic equilibrium between
oligomers and ﬁbrils during aggregation have been provided [119].
It was suggested that the intensity ratio between the two spectral
contributions of β-structure (I1695/I1630) is proportional to the percent-
age of anti-parallel vs. parallel organization of the β-strands; therefore
we tentatively called this ratio the “β-sheet organizational index”. Be-
cause in amyloid, anti-parallel vs. parallel is also proportional to oligo-
mer to ﬁbril contents we used this index to roughly determine the
percentage of oligomers in a sample [91]. The ‘β-sheet organizational
index’ has been applied with success to the study of α-synuclein oligo-
mers [33], or Aβ in the presence of exogenous compounds like other
proteins such as apoliprotein E isoforms [149] or ions (Ca2+) [150].
We are convinced this ‘β-sheet organizational index’ can ﬁnd many
more applications in future amyloid studies.
As ﬁrst and cleverly suggested by Torleif Härd's group [31,151], and
in accordance with our own results [29,91] the “simplest” way to de-
scribe the conformational change from anti-parallel to parallel β-sheet
could be explained by a 90° rotation of the involved β-strands.
5. Conclusion
We tried to emphasize the role of FTIR and especially ATR-FTIR
techniques in the study of amyloid proteins and/or peptides. Themulti-
ple advantages provided by ATR-FTIR allow an almost continuous
structural view of protein/peptide conversion during the aggregation
process. Isotope-edited FTIR can even provide structural information
at the amino acid level. Moreover, it is now well-established that infra-
red can differentiate oligomers from ﬁbrils simply on their spectral fea-
tures. Today, ATR-FTIR is certainly the fastest and easiest method to
obtain this information. ATR-FTIR was indeed the ﬁrst method to reveal
that, contrary to ﬁbrils, oligomers adopt an anti-parallel β-sheet confor-
mation. This speciﬁc conformation is nowwell-correlatedwith cytotox-
ic effects of the oligomeric species.
ATR-FTIR is deﬁnitely an extremely versatile tool to study amyloids
and will continue in the near future to provide new information on
these proteins and peptides. It has its own place (in complement to
higher resolution methods) in the analysis and comprehension of the
complex aggregation mechanism(s) at the oligomer and/or ﬁbril level.
These mechanism(s) seem to demonstrate similarities between differ-
ent amyloid proteins and might therefore be extremely important to-
wards the understanding of both disease-associated and functional
amyloid proteins.
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